Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Period A · 1 trial · 2 indications
Apnea-hypopnea index based on 4% hypopnea desaturation
| Arm | Type | Description |
|---|---|---|
| Order: Period A, Period B, Period C | EXPERIMENTAL | The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week). |
| Order: Period B, Period C, Period A | EXPERIMENTAL | The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week). |
| Order: Period C, Period A, Period B | EXPERIMENTAL | The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week). |
| Order: Period A, Period C, Period B | EXPERIMENTAL | The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week). |
| Order: Period B, Period A, Period C | EXPERIMENTAL | The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week). |
| Order: Period C, Period B, Period A | EXPERIMENTAL | The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week). |
| Name | Type | Description |
|---|---|---|
| Period A | DRUG | Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo |
| Period B | DRUG | Week 1: AD816 low dose; Week 2: AD816 high dose |
| Period C | DRUG | Week 1: Placebo + Placebo; Week 2: Placebo + Placebo |
Inclusion Criteria: 1. Between 18 to 75 years of age, inclusive, at the Screening Visit 2. PSG criteria (V2 only) 1. AHI4 (Hypopneas defined by 4% oxygen desaturation) of 10-45, inclusive 2. ≤25% of events are central or mixed apneas 3. PROMIS Fatigue or sleep related impairment or sleep dis...